AdaptHealth Corp. reported first‑quarter 2026 results on May 5, 2026, with revenue of $819.8 million—$21.7 million above the consensus estimate of $798.14 million—while earnings per share fell to a loss of $0.12, a miss against the $0.00 to $0.01 estimate. The company also raised its full‑year 2026 revenue guidance to $3.45 billion–$3.52 billion, a modest $10 million increase over the prior outlook.
Revenue growth was driven by a 9.1% year‑over‑year increase, largely fueled by the accelerated transition of a large capitated contract and robust performance in the Sleep Health segment. The new contract, described as the largest patient transition in the home medical equipment industry, added significant top‑line momentum and helped offset weaker performance in legacy product lines. Organic revenue growth accelerated from a 1.4% decline in the prior‑year quarter to a healthy 9.1% gain, underscoring the company’s ability to capture demand across its four operating segments.
The EPS miss was primarily caused by elevated labor costs and transition expenses associated with the capitated contract rollout. Adjusted EBITDA fell to $121.2 million, yielding a margin of 14.8%—160 basis points lower than the 16.4% margin reported in the same quarter a year earlier. The margin contraction reflects the company’s investment in workforce expansion and integration costs that have not yet been fully absorbed by the new contract’s revenue stream.
Free cash flow turned negative at $27.5 million, a sharp deterioration from the near‑breakeven figure reported a year earlier. The negative cash flow is a consequence of the higher operating expenses and the capital outlays required to support the capitated contract transition, which have temporarily outweighed the revenue gains.
Management signaled confidence in a rebound of profitability, noting that the company expects margin recovery in the second half of 2026 as the transition costs normalize. The guidance for full‑year revenue was raised by $10 million, while Adjusted EBITDA and free‑cash‑flow guidance were maintained, indicating that the company believes its cost‑control initiatives will translate into improved operating performance.
Investors reacted negatively to the earnings release, with the market focusing on the EPS miss and margin compression. The loss per share and the 160‑basis‑point decline in adjusted EBITDA margin were viewed as evidence of ongoing cost pressure, prompting a sell‑off in the company’s shares.
Additional context highlights a $1.1 billion refinancing of the senior secured credit facility completed in April 2026, which is expected to reduce near‑term amortization obligations and lower the weighted average cost of debt. The company also reported a 26% increase in registered myApp users, reaching 412,000, and continued to divest non‑core assets such as custom rehabilitation equipment to focus on its core Sleep and Respiratory Health businesses. These moves reinforce AdaptHealth’s strategy to streamline operations and invest in high‑growth segments.
"The opening months of 2026 have set the stage for what will be a defining year for AdaptHealth. We completed the largest de novo expansion in the history of the home medical equipment industry, delivering revenue well ahead of our first‑quarter guidance, with broad‑based organic growth across all four segments. Although we incurred elevated labor costs to execute the transition responsibly, we are already working to optimize the business for our newly attained scale," said CEO Suzanne Foster. "First quarter adjusted EBITDA was $121.2 million, representing an adjusted EBITDA margin of 14.8% and coming in about $7 million lower than guidance," added CFO Jason Clemens.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.